AbbVie Inc. (ABBV)
2 High-Yield Dividend Stocks to Buy Right Now
High-yield dividend stocks typically outperform the broader markets over long periods. AbbVie and Pfizer are two attractively priced high-yield dividend stocks worth considering right now.
The Dividend Dominators: 3 Stocks That Will Make Your Portfolio Reign Supreme
The timing is perfect for loading up on dividend stocks as market experts expect the S&P 500 to increase 4% in June following a 5% rise in May as three potential rate cuts loom, possibly boosting already solid corporate profitability. Meanwhile, 97% of S&P 500 companies reported first-quarter results that were 3% better than consensus.
AbbVie (ABBV) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
7 Overlooked Stocks That Belong in Every Portfolio
The financial media does its best to keep you informed about what's happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards.
AbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
3 No-Brainer Stocks to Buy in June
AbbVie covers all the bases for investors -- income, value, and growth. AstraZeneca is an inexpensive stock that has solid growth opportunities.
AbbVie: Turnaround Lurking After The Correction Pain (Upgrade)
AbbVie stock has fallen into a correction, declining nearly 16% from its March 2024 highs. Despite the pullback, AbbVie remains a highly profitable company with a strong portfolio and robust long-term guidance. The stock valuation is not cheap, but ABBV's 4% dividend yield may provide valuation support.
3 Dividend Stocks to Double Up on Right Now
AbbVie is a Dividend King in good shape to deliver solid growth through the rest of the decade. Chevron should reward investors with growing dividends and the "invisible dividends" of stock buybacks.
Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered
AbbVie, a key player in my dividend growth portfolio, boasts a strong 4% yield and a consistent record of annual hikes. Its robust product lineup and innovative pipeline promise growth. Despite losing Humira's patent, AbbVie's new drugs, Skyrizi and Rinvoq, drive impressive revenue growth. The company continues to outperform the market with a solid return profile. Trading at a reasonable P/E ratio, AbbVie combines growth potential and reliable income.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
7 Biotech Stocks to Put on Your Breakthrough Radar
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.
